EGFR exon 20 insertion

Should you test for EGFR exon 20 and NRG1 with DNA- or RNA-based NGS? Check out https://t.co/NFJ4GmvKuu to hear from @EdgardoSantosMD, of @FLASCO_ORG, #ILCC #lcsm #gotoPER @FloridaAtlantic (@OncLive)

Congrats to @APassaroMD & authors: https://t.co/xRnnGprcc9 Most oncologists handling #EGFR #Exon20 avoid IO in 1L. #PAPILLON & #EXCLAIM2 Ph 3's have the correct comparator: the doublet! Please all: Let us know if you have exceptional IO responders w/any EGFR ex 20 variant. #LCSM https://t.co/8q2dn61rH5 (@Exon20Group)

Honored to write an invited editorial on "Zipalertinib in EGFR Exon 20–Mutant NSCLC" - out now in @JCO_ASCO @ASCO @StephenVLiu - we discuss the role of novel TKIs, and drug development in this rare, but increasingly crowded space! Congrats to the authors on this important… https://t.co/q2gu83PHLN (@CharuAggarwalMD)

I disagree with the FLAURA-2 analogy. The difference here is that targeted therapies for #EGFR exon 20 #NSCLC are no where near as good as sensitizing EGFR alterations. We should be comparing this data to Ph2 Chrysalis, where all participants got chemo first. (@TejasPatilMD)

For more on this subset of lung cancer, be sure to listen to this episode of Lung Cancer Considered, the @IASLC podcast, where I discuss #EGFR exon 20 insertion NSCLC with Dr. Byoung Cho, Dr. Rosario Campelo @charocampelo and Marcia Horn @Exon20Group. https://t.co/i16OujxoC7 (@StephenVLiu)

Updates to the @ASCO Living Guidelines on Therapy for Stage IV NSCLC with Driver Alterations now @JCO_ASCO. Additions include amivantamab and mobocertinib for #EGFR exon 20 insertion NSCLC and sotorasib for #KRAS G12C NSCLC. https://t.co/NdWku4z9BU (@StephenVLiu)

Latest living guideline update on stage IV NSCLC just published. Listen to Dr. @ns_chd share the new updates - including second-line options for patients with EGFR exon 20 insertions or KRAS G12C mutations - & the rationale in our latest podcast episode https://t.co/yIzwf6akKb (@BrittanyEHarvey)

Zipalertinib in Lung Cancer Harboring EGFR Exon 20 Insertions https://t.co/ogKdpiWqFm. Responses seen from starting till the final dose level. Another agent apart from Amivatinab, poziotinib and mobocertinib @JCO_ASCO @LungConnectIN (@DrVijayPatil11)

Here is what happened to 73 patients with EGFR exon20 insertions treated with Zipalertinib in a phase I/2a study. #lcsm @ZPiotrowskaMD https://t.co/e7nwt4FYFd (@DrewMoghanaki)

#LATAMOncoSummit #LOS2023 Mexico city Great opportunity to learn more about #egfrexon20 #lungcancer from this amazing team. @ClaudioVladmir, Hatin Husain, @CPupareli, @GonzaloRecondo, William William, @GlopesMd (@drfuzita)

Results from phase I/II study of zipalertinib (CLN-081) in #EGFR exon 20 insertion NSCLC @JCO_ASCO. RR 38%; TRAEs include rash (80%), paronychia (32%), diarrhea (30%). At a zipalertinib dose of 100mg bid (oral), RR was 41% and no G3+ rash/diarrhea. https://t.co/S2OkALQNb8 (@StephenVLiu)

@CoreyLangerMD on behalf of @JSabari summarizes targeted therapies available in the EGFR exon 20 insertion NSCLC space. 👇🏽 Excellent summary slide to save #DAVAHawaiiLung #lcsm (@esinghimd)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/7Xpzj7KaFx. (@cancerGRACE)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/3VETMT8eM4. (@cancerGRACE)

I really like this retrospective study in @JTOonline on #EGFR Exon 20 #lungcancer. PCR tests misses MANY EGFR variants; highlights importance of comprehensive (not piecemeal) #NGS testing. @lcsmchat @EGFRResisters 👉🏾https://t.co/WsJEnbz6cv (@TejasPatilMD)

I have a case i would like to share and I need assistance. 70 years old non smoker female with stage IV NSCLC ( adenocarcinoma) EGFR exon 20 ins by NGS. What’s the recommendation for as regard 1st line ? @APassaroMD 🙏 (@omarmokhtar89)

Sunvozertinib EGFR exon20 ins inhibitor -ORR 60.8% across exon20ins subtypes -cORR 48.5% in pts with CNS mets -toxicity profile w/ high rates of diarrhea, rash, anemia #ASCO23 #LCSM @AnaVManana (@OncLive)

Dr. Jonathan Riess @riess_md with an excellent discussion of impt unanswered questions in EGFRm NSCLC space including utility of IO, optimal mgmt of brain metastases and evolving Rx strategies in EGFRex20ins. #ASCO23 @EGFRResisters @Exon20Group (@Joshua_Reuss)

Amazing analysis by MD Riess at #ASCO23 about the first pivotal study that confirmed sunvozertinib is superior anti-tumor efficacy than the current available therapy for NSCLC with EGFR exon20ins 🙌 (@Dr_Ivanoncologo)

“Whether through tissue or liquid biopsy testing you need those biomarker results before making therapeutic treatment decisions…” esp in #lungcancer #EGFR exon20 or rare mutations https://t.co/vlgXWzG1b0 @LuisERaez1 Dr. Chandra @PathGroupLabs @JanssenUS (@PMPbyTrapelo)

#ASCO23 @ASCO Poster Discussion #NSCLC phase I/II trial of YK-029A in #EGFR exon20, or rare mutations ➡️ impressive efficacy seen t/t naive Ex20 @Exon20Group @LeXiuning @OncoAlert (@CharuAggarwalMD)

#NSCLC #EGFR #Exon20 new 3rd generation #EGFRTKI announced at #ASCO2023 YK-029A via presentations from Dr. Duan, see Abstract 9014, and great summary by @LeXiuning Congratulations! (@Exon20Group)

Thank you Mark for your work and compassion 🙏 Soon Mi Wolff (1965-2019) Lung Cancer (never smoker) EGFR Exon 20 Tarloxotinib: Phase 2 Clinical Trial (April - September 2019) I said goodbye to your body but never to us ❤️❤️❤️ (@kevinwolffCGN9)

#ASCO23 @ASCO Abs#9002 Results of DZD9008 - sunvozertinib in pts w/ exon 20 #EGFR mutation @Exon20Group ➡️ Median 2L of prior tx ➡️ ORR ~ 61%, N=100 ➡️ ORR 48.5% in baseline brain mets ➡️ DoR 11 mo #LCSM https://t.co/ZfJY1gbtoS @OncoAlert @HemOncToday (@CharuAggarwalMD)

🔝 Sunvozertinib's superior anti-tumor efficacy outperforms current available therapy for NSCLC with EGFR exon20 insertion mutations. We're eagerly waiting for more data from this study and others around the world. 🌍 #ASCO23 #oncology #NSCLC" (@CAudigierValett)

📢 Breaking news from #ASCO23: The first pivotal study results are in for Sunvozertinib (DZD9008), a selectively designed EGFR exon20 insertion inhibitor, for the treatment of NSCLC. This is a major step in targeted cancer therapies. 🎯 #cancerresearch #NSCLC (@CAudigierValett)

Listen as Dr @MarkSocinski discusses recently approved targeted therapies into current treatment algorithms for patients with mNSCLC EGFR Exon 20 insertion mutations and ongoing results from clinical trials. https://t.co/pj2F4uaJG8 #oncology #lungcancer (@ClinicalCareSol)

NSCLC with an #EGFR exon 20 insertion mutation is different from exon 19 deletion and exon 21 L858R! Drs. Byoung-Chul Cho and @charocampelo describe their approach and Marcia Horn @Exon20Group provides perspective in this episode of #LungCancerConsidered https://t.co/i16OujxoC7 (@StephenVLiu)

#Lungcancer biomarkers and sub-mutation in those biomarkers? Hear #EGFR leading expert @DCarboneMD of @OSUWexMed @OSUCCC_James explain the most common submutations for the EGFR biomarker, Exon 20 and Exon 19: https://t.co/4q8bFOUTH3 (@lcfamerica)

#Lungcancer biomarkers and sub-mutation in those biomarkers? Hear #EGFR leading expert @DCarboneMD of @OSUWexMed @OSUCCC_James explain the most common submutations for the EGFR biomarker, Exon 20 and Exon 19: https://t.co/4q8bFOUTH3 (@lcfamerica)

Dr. @charocampelo gives an update on #EGFR exon 20 insertion NSCLC at #RomeLung23. Amivantamab and mobocertinib now approved but modest response rates. Newer agents coming like zipalertinib (CLN-081) and sunvozertinib (DZD9008). And despite data, IO is often used in real world. (@StephenVLiu)

🌟 After recent connection of air pollutants with carcinogenesis in @EGFR mut #NSCLC, we must identify causes of #EGFRexon20 NSCLC: In @JTOonline we propose to investigate pts in #EXOTIC DB for environmental determinants: kick-off! @IASCL @myESMO #some https://t.co/k7HI4WfGPm (@g_mountzios)

🚨Catch up on the latest #LungCancer session on-demand! Hear from @DrSanjayPopat @AlastairGreyst2 @Anna_Minchom and @DrRiyazShah as they discuss identification of EGFR exon 20 insertions and how to manage patients in the UK. Watch 👉 https://t.co/Zdk5GC8YMC 💻 @BTOGORG #LCSM (@VJOncology)

Dr. Amin Benyounes with a comprehensive overview of EGFR exon20 and NRG1 in NSCLC at #OncLiveSOSS. Great to see approved and emerging therapies in these populations, but we must continue to advance Rxs in these and other rare populations that lack efficacious therapeutics. (@Joshua_Reuss)

7/21 #TumorBoardTuesday #LungCancer #LCSM 👩🏻‍🏫Mini tweetorial 4 👩🏼‍🏫 📌EGFR exon 20 insertions/mutations 📍Most are diverse group of in-frame duplication or insertion muts 📍Associated with response to specific 🎯 subsequent therapy (@JennyCarlisleMD)

5/5 #TumorBoardTuesday Thurs Case🎀 🙏 More options, guided by 🎯 onc to ⬇️ risk of #BreastCancer recurrence ➡️Join us on April 25: @LealTiciana @JennyCarlisleMD are discussing #EGFR Exon 20ins treatment in #NSCLC! (@JohnEbbenMDPhD)

Going to the #AACR23 session on Advances in #NSCLC? Lots of activity in the #EGFR #exon20 space, e.g. this phase 1/2 trial in @CD_AACR: Activity and safety of mobocertinib (TAK-788) in previously treated NSCLC with EGFR exon20 insertion mutations @RielyMD https://t.co/rfswU55fok (@ElizSMcKenna)

Make sure you catch up on the latest #LungCancer session!🩺 Hear from @DrSanjayPopat @AlastairGreyst2 @Anna_Minchom and @DrRiyazShah as they discuss identification of EGFR exon 20 insertions and how to manage patients in the UK. Watch 💻 https://t.co/XG43gjjmH4 @BTOGORG #LCSM (@VJOncology)

Amivantamab efficacy in pretreated NSCLC with EGFR Exon 20 insertion mutations persists long term https://t.co/NApQKi7B1v (@AndresFCardonaZ)

🚨🔥 2/3 Long-term analysis of #Amivantamab in #patients with #EGFR Exon 20 insertion mutated #NSCLC. #CHRYSALIS Study: • Median #PFS: 6.9 months • Median #OS: 23 months • 2-yr #OS: 47.2% • 13% of pts remained on treatment for a median duration of 2.6 years #LCSM (@RManochakian)

🚨🔥3/3 Long-term analysis of #Amivantamab in #patients with #EGFR Exon 20 insertion mutated #NSCLC. Link to #ELCC23 abstract: 👉 https://t.co/AF68zt7TSJ Link to @ASCOPost article: 👉 https://t.co/iWMfhisFmP @EGFRResisters @Exon20Group #LungCancer #KnowledgeConquersCancer (@RManochakian)

🚨🔥1/3 Hot off the press #Abstract/presentation at #ELCC23 @myESMO by @Piuchagarrido et al & report article about it @ASCOPost. Long-term analysis of #Amivantamab in #patients with #EGFR Exon 20 insertion mutated #NSCLC. Summary & links to abstract & article in thread below👇🏼 (@RManochakian)